ArticleChemical science2026
Exploring RNA G-quadruplex in the rabies virus genome and its potential against RABV infection.
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabies virus (RABV) is a prototypical neurotropic RNA virus that can cause rabies with an almost 100% fatality rate. Despite great efforts having been made to identify an effective therapeutic target of rabies, the host factors involved in RABV infection and the underlying mechanisms remain poorly understood. There are no effective drug targets for human rabies to date. Therefore, a better understanding of rabies pathogenesis and exploring new targets for antiviral treatments are crucial and urgent. In this study, we identify the presence of G-quadruplex (G4) in the RABV genome and uncover a novel role of G4 in RABV infection, in which stabilization of G4 can suppress G protein translation and viral replication. By systematic screening of 10 pairs of triplex metallohelices (designated as M1-M10), we found that one enantiomer of a pair of glycoconjugated metallohelices (Λ-M10) has exceptional RABV G4-stabilizing ability. Further studies show that Λ-M10 exhibits potent antiviral activity against RABV by targeting viral RNA G4s while maintaining minimal cytotoxicity in RABV-infected cell lines. More interestingly, having a nanosized structure and glycoconjugated modifications, M10 could cross the blood-brain barrier, supporting the potential in clinical therapy for RABV infection. Our findings elucidate the presence of G4 in the RABV genome, which can be targeted by G4 ligands such as metallohelices to suppress crucial G protein translation and viral replication, a previously unrecognized mechanism against RABV infection.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.